A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Blood

Topics

Medicine

Materials Science

Cancer Oncology

Internal Medicine

Hematology

Show all topics

DOI

10.1182/blood-2012-05-425934